Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
Primary Purpose
Amyotrophic Lateral Sclerosis
Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Skin biopsy
Cardiovascular Reflexes testing
Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Dinamic Sweat Test
Sponsored by
About this trial
This is an interventional basic science trial for Amyotrophic Lateral Sclerosis focused on measuring Autonomic nervous system, skin biopsy, biomarkers, cutaneous sensory an autonomic innervation
Eligibility Criteria
Inclusion Criteria: ALS patients will be recruited within 18 months from the motor symptoms onset Exclusion Criteria: glucose intolerance or conditions potentially affecting the peripheral nervous system
Sites / Locations
- ICS Maugeri - IRCCS of Telese TermeRecruiting
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico IIRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Amyotrophic Lateral Sclerosis patients
Healthy controls
Arm Description
Amyotrophic Lateral Sclerosis (ALS) patients within 18 months from symptoms onset will be recruited
A population of healthy controls matched for sex and age will be enrolled
Outcomes
Primary Outcome Measures
Sensory peripheral innervation (IENF)
Quantification Intraepidermal Nerve Fibers (IENF ff/mm) in skin biopsy from fingertip, thigh and leg.
Autonomic peripheral innervation
Quantification of nerves in sweat gland (fiber lenght/um3) in skin biopsy from fingertip, thigh and leg.
Quantification of nerves in arrector pili muscle (ff/mm) in skin biopsy from thigh and leg.
Autonomic peripheral innervation
Quantification sweat gland (fiber lenght/um3) and arrector pili muscle (ff/mm) innervation in skin biopsy from thigh.
Sensory peripheral innervation (IENF)
Quantification Intraepidermal Nerve Fibers (IENF ff/mm) in skin biopsy from thigh.
Secondary Outcome Measures
Sensory and autonomic symptoms evaluated by clinical scales
Data of sensory and autonomic symptoms (Small fiber neuropathy Symptoms inventory questionnaire (SFN-SIQ) and Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA AUT)) will be collected
Sensory and autonomic symptoms evaluated by clinical scales
Data of sensory and autonomic symptoms (Small fiber neuropathy Symptoms inventory questionnaire (SFN-SIQ) and Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA AUT)) will be collected
Assessment of Cardiovascular function
Data from cardiovascular reflex test will be analyzed and compared with morphological data and clinical motor severity
Sudomotor function
Data from dinamic sweat test will be analyzed and compared with morphological data and clinical motor severity
Full Information
NCT ID
NCT05747937
First Posted
January 26, 2023
Last Updated
February 17, 2023
Sponsor
Istituti Clinici Scientifici Maugeri SpA
1. Study Identification
Unique Protocol Identification Number
NCT05747937
Brief Title
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
Official Title
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 15, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
May 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituti Clinici Scientifici Maugeri SpA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this interventional non-pharmacological study is to evaluate, using a multimodal approach, the progression of autonomic and sensory involvement in in amyotrophic lateral sclerosis (ALS) patients enrolled within 18 months from motor onset and its relationship with the progression of overall clinical disability.
The main questions it aims to answer are:
Is autonomic dysfunction at diagnosis associated with disease progression and survival in patients with Amyotrophic Lateral Sclerosis ?
Can we identify in the skin biomarkers to be used as reliable measures of disease progression and to apply in future clinical trials for patient stratification and to assess response to drug treatment ? Participants at time 0 will receive a full clinical and instrumental examination and a blood sample testing to check inclusion and exclusion criteria, genetic screening for the most common genes associated with ALS (SOD1, FUS, TARDBP and c9orf72), questionnaires about clinical characteristics, quality of life, pain and a multidomain battery of neuropsychological tests, multimodal assessment of the autonomic nervous system including skin biopsy for morphological study. At follow-up we'll perform clinical scales and skin biopsy.
Researchers will compare results from ALS patients with data obtained from a population of age and sex matched healthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis
Keywords
Autonomic nervous system, skin biopsy, biomarkers, cutaneous sensory an autonomic innervation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Masking Description
There are not masking participants
Allocation
Non-Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Amyotrophic Lateral Sclerosis patients
Arm Type
Experimental
Arm Description
Amyotrophic Lateral Sclerosis (ALS) patients within 18 months from symptoms onset will be recruited
Arm Title
Healthy controls
Arm Type
Active Comparator
Arm Description
A population of healthy controls matched for sex and age will be enrolled
Intervention Type
Diagnostic Test
Intervention Name(s)
Skin biopsy
Intervention Description
A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
Intervention Type
Diagnostic Test
Intervention Name(s)
Cardiovascular Reflexes testing
Intervention Description
Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
Intervention Type
Diagnostic Test
Intervention Name(s)
Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Intervention Description
We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
Intervention Type
Diagnostic Test
Intervention Name(s)
Dinamic Sweat Test
Intervention Description
Test for the functional assessment of postganglionic sudomotor pathway
Primary Outcome Measure Information:
Title
Sensory peripheral innervation (IENF)
Description
Quantification Intraepidermal Nerve Fibers (IENF ff/mm) in skin biopsy from fingertip, thigh and leg.
Time Frame
At recruitment
Title
Autonomic peripheral innervation
Description
Quantification of nerves in sweat gland (fiber lenght/um3) in skin biopsy from fingertip, thigh and leg.
Quantification of nerves in arrector pili muscle (ff/mm) in skin biopsy from thigh and leg.
Time Frame
At recruitment
Title
Autonomic peripheral innervation
Description
Quantification sweat gland (fiber lenght/um3) and arrector pili muscle (ff/mm) innervation in skin biopsy from thigh.
Time Frame
At follow-up, an average of 6 months
Title
Sensory peripheral innervation (IENF)
Description
Quantification Intraepidermal Nerve Fibers (IENF ff/mm) in skin biopsy from thigh.
Time Frame
At follow-up, an average of 6 months
Secondary Outcome Measure Information:
Title
Sensory and autonomic symptoms evaluated by clinical scales
Description
Data of sensory and autonomic symptoms (Small fiber neuropathy Symptoms inventory questionnaire (SFN-SIQ) and Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA AUT)) will be collected
Time Frame
At the recruitment
Title
Sensory and autonomic symptoms evaluated by clinical scales
Description
Data of sensory and autonomic symptoms (Small fiber neuropathy Symptoms inventory questionnaire (SFN-SIQ) and Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA AUT)) will be collected
Time Frame
At follow-up, an average of 6 months
Title
Assessment of Cardiovascular function
Description
Data from cardiovascular reflex test will be analyzed and compared with morphological data and clinical motor severity
Time Frame
baseline
Title
Sudomotor function
Description
Data from dinamic sweat test will be analyzed and compared with morphological data and clinical motor severity
Time Frame
baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
ALS patients will be recruited within 18 months from the motor symptoms onset
Exclusion Criteria:
glucose intolerance or conditions potentially affecting the peripheral nervous system
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Nolano, MD, PhD
Phone
+390824909257
Email
maria.nolano@icsmaugeri.it
First Name & Middle Initial & Last Name or Official Title & Degree
Giuseppe Caporaso
Phone
+390824909645
Email
giuseppe.caporaso@icsmaugeri.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Nolano, MD, PhD
Organizational Affiliation
Istituti Clinici Scientifici Maugeri SpA
Official's Role
Principal Investigator
Facility Information:
Facility Name
ICS Maugeri - IRCCS of Telese Terme
City
Telese Terme
State/Province
Benevento
ZIP/Postal Code
82037
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincenzo Provitera, MD
Phone
+390824909257
Email
vincenzo.provitera@icsmaugeri.it
Facility Name
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raffaele Dubbioso, MD
Phone
0817464587
Email
raffaele.dubbioso@unina.it
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33993457
Citation
Mahoney CJ, Ahmed RM, Huynh W, Tu S, Rohrer JD, Bedlack RS, Hardiman O, Kiernan MC. Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs. 2021 May;35(5):483-505. doi: 10.1007/s40263-021-00820-1. Epub 2021 May 15.
Results Reference
background
PubMed Identifier
31293369
Citation
Gentile F, Scarlino S, Falzone YM, Lunetta C, Tremolizzo L, Quattrini A, Riva N. The Peripheral Nervous System in Amyotrophic Lateral Sclerosis: Opportunities for Translational Research. Front Neurosci. 2019 Jun 25;13:601. doi: 10.3389/fnins.2019.00601. eCollection 2019.
Results Reference
background
PubMed Identifier
26908600
Citation
Sassone J, Taiana M, Lombardi R, Porretta-Serapiglia C, Freschi M, Bonanno S, Marcuzzo S, Caravello F, Bendotti C, Lauria G. ALS mouse model SOD1G93A displays early pathology of sensory small fibers associated to accumulation of a neurotoxic splice variant of peripherin. Hum Mol Genet. 2016 Apr 15;25(8):1588-99. doi: 10.1093/hmg/ddw035. Epub 2016 Feb 9.
Results Reference
background
PubMed Identifier
21646630
Citation
Weis J, Katona I, Muller-Newen G, Sommer C, Necula G, Hendrich C, Ludolph AC, Sperfeld AD. Small-fiber neuropathy in patients with ALS. Neurology. 2011 Jun 7;76(23):2024-9. doi: 10.1212/WNL.0b013e31821e553a.
Results Reference
background
PubMed Identifier
25683764
Citation
Truini A, Biasiotta A, Onesti E, Di Stefano G, Ceccanti M, La Cesa S, Pepe A, Giordano C, Cruccu G, Inghilleri M. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. J Neurol. 2015;262(4):1014-8. doi: 10.1007/s00415-015-7672-0. Epub 2015 Feb 17.
Results Reference
background
PubMed Identifier
27288647
Citation
Nolano M, Provitera V, Manganelli F, Iodice R, Caporaso G, Stancanelli A, Marinou K, Lanzillo B, Santoro L, Mora G. Non-motor involvement in amyotrophic lateral sclerosis: new insight from nerve and vessel analysis in skin biopsy. Neuropathol Appl Neurobiol. 2017 Feb;43(2):119-132. doi: 10.1111/nan.12332. Epub 2016 Jul 7.
Results Reference
background
PubMed Identifier
33372053
Citation
deCarvalho M, Gromicho M, Andersen P, Grosskreutz J, Kuzma-Kozakiewicz M, Petri S, Uysal H, Pinto S. Peripheral neuropathy in ALS: phenotype association. J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1133-1134. doi: 10.1136/jnnp-2020-325164. Epub 2020 Dec 28. No abstract available.
Results Reference
background
PubMed Identifier
27964824
Citation
Chio A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017 Feb;16(2):144-157. doi: 10.1016/S1474-4422(16)30358-1. Epub 2016 Dec 8.
Results Reference
background
PubMed Identifier
32897040
Citation
Fasolino A, Di Stefano G, Leone C, Galosi E, Gioia C, Lucchino B, Terracciano A, Di Franco M, Cruccu G, Truini A. Small-fibre pathology has no impact on somatosensory system function in patients with fibromyalgia. Pain. 2020 Oct;161(10):2385-2393. doi: 10.1097/j.pain.0000000000001920.
Results Reference
background
PubMed Identifier
27115670
Citation
Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016 Aug;157(8):1599-1606. doi: 10.1097/j.pain.0000000000000492.
Results Reference
background
PubMed Identifier
22236582
Citation
Damon-Perriere N, Foubert-Samier A, De Cock VC, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison F, Meissner WG. Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord. 2012 Jun;18(5):612-5. doi: 10.1016/j.parkreldis.2011.12.009. Epub 2012 Jan 9.
Results Reference
background
PubMed Identifier
11464847
Citation
Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. doi: 10.1080/146608200300079536. No abstract available.
Results Reference
background
Learn more about this trial
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
We'll reach out to this number within 24 hrs